Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Randomized Double-blind Placebo Controlled Trial Evaluating the Effect of Nivolumab for Patients With In-transit Melanoma Metastases Treated With Isolated Limb Perfusion - the NivoILP Trial

NCT03685890 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT03685890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03685890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Randomized Double-blind Placebo Controlled Trial Evaluating the Effect of Nivolumab for Patients With In-transit Melanoma Metastases Treated With Isolated Limb Perfusion - the NivoILP Trial
Lead sponsor
Vastra Gotaland Region
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 1, 2019
Completion date
December 31, 2029
Enrollment
74 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

in-transit metastasis, melanoma